Red Light Holland Partners with Kala Bio for PEX010 Clinical Development

Red Light Holland has engaged Kala Bio's Researgency.ai platform to support the clinical development strategy for PEX010, a patented botanical psilocybin drug candidate originated by Filament Health. The platform will deploy AI-powered autonomous research agents to assist in clinical planning, protocol optimization, and scenario modeling as Red Light advances PEX010 through its regulated drug development program. This move aims to accelerate and enhance research planning and protocol optimization processes associated with advancing PEX010 through Filament's clinical development pipeline.